Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, Kreyenberg H, Schubert R, Quadflieg M, Schneider D, Kühn MWM, Penack O, Zhang C, Möker N, Ullrich E. Albinger N, et al. Among authors: kuhn mwm. Blood Cancer J. 2022 Apr 13;12(4):61. doi: 10.1038/s41408-022-00660-2. Blood Cancer J. 2022. PMID: 35418180 Free PMC article.
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Krönke J, et al. Blood. 2013 Jul 4;122(1):100-8. doi: 10.1182/blood-2013-01-479188. Epub 2013 May 23. Blood. 2013. PMID: 23704090 Free article.
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, Chen CW, Mupo A, Hähnel P, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MWM. Dzama MM, et al. Among authors: kuhn mwm. Blood. 2020 Nov 19;136(21):2442-2456. doi: 10.1182/blood.2020005037. Blood. 2020. PMID: 32589720 Free PMC article.
Unleashing the power of NK cells in anticancer immunotherapy.
Vogler M, Shanmugalingam S, Särchen V, Reindl LM, Grèze V, Buchinger L, Kühn M, Ullrich E. Vogler M, et al. J Mol Med (Berl). 2022 Mar;100(3):337-349. doi: 10.1007/s00109-021-02120-z. Epub 2021 Aug 9. J Mol Med (Berl). 2022. PMID: 34374809 Free PMC article. Review.
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.
Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. Dolnik A, et al. Blood. 2012 Nov 1;120(18):e83-92. doi: 10.1182/blood-2011-12-401471. Epub 2012 Sep 13. Blood. 2012. PMID: 22976956 Free article.
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin.
Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik VI, Schlenk RF, Paschka P, Weber D, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Ramachandran D, Benner A, Ganser A, Döhner H, Heuser M, Döhner K, Thol F. Teich K, et al. Among authors: kuhn mwm. Haematologica. 2021 Nov 1;106(11):2986-2989. doi: 10.3324/haematol.2021.278894. Haematologica. 2021. PMID: 34047179 Free PMC article. No abstract available.
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Döhner H, et al. Among authors: kuhn mwm. Blood Adv. 2022 Sep 27;6(18):5345-5355. doi: 10.1182/bloodadvances.2022007223. Blood Adv. 2022. PMID: 35486475 Free PMC article. Clinical Trial.
22 results